Want to see HK:3692 full AI Analyst Report?
Hansoh Pharmaceutical Group Company Limited (3692) AI Stock Analysis
Top Page
Hansoh Pharmaceutical Group Company Limited
(HKEX:3692)
The score is driven primarily by strong financial performance (high profitability, very low leverage, and solid 2025 cash generation). This is tempered by weaker technical momentum signals (negative MACD and sub-50 RSI) and a moderately expensive valuation (P/E 26.6 with only a ~1.41% dividend yield).
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 196.19B
- Dividend Yield
- 1.50%
- Average Volume (3M)
- 11.13M
- Price to Earnings (P/E)
- 25.0
- Beta (1Y)
- 0.57
- Revenue Growth
- 24.97%
- EPS Growth
- 43.23%
- Country
- Hong Kong
- Employees
- 9,643
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Company Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas,...
How the Company Makes Money
Hansoh primarily makes money by selling pharmaceutical products (mainly prescription medicines) in mainland China. Revenue is generated from (1) in-house manufactured finished drugs sold to customers via the company’s commercialization network and th...
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
Summary
Strong overall fundamentals supported by re-accelerating 2025 revenue growth (+11%), exceptionally high and consistent profitability (gross margin ~90%, net margin mid-to-high 30s), very low leverage (debt-to-equity ~0.3% in 2025), and solid 2025 cash conversion (OCF ~1.53x net income). Main risk is year-to-year volatility in margins and cash conversion (notably weak OCF coverage in 2023).
Income Statement
88Very PositiveBalance Sheet
93Very PositiveCash Flow
86Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.90B | 15.03B | 12.26B | 10.10B | 9.38B | 9.94B |
| Gross Profit | 14.38B | 13.51B | 11.16B | 9.07B | 8.51B | 9.06B |
| EBITDA | 6.33B | 5.79B | 4.30B | 4.20B | 2.94B | 3.08B |
| Net Income | 6.68B | 5.56B | 4.37B | 3.28B | 2.58B | 2.71B |
Balance Sheet | ||||||
| Total Assets | 46.60B | 39.92B | 31.66B | 33.04B | 30.00B | 27.16B |
| Cash, Cash Equivalents and Short-Term Investments | 37.38B | 31.58B | 23.39B | 24.86B | 21.63B | 18.94B |
| Total Debt | 4.23B | 105.14M | 117.89M | 4.30B | 4.38B | 3.83B |
| Total Liabilities | 8.84B | 4.54B | 2.98B | 7.24B | 7.35B | 7.13B |
| Stockholders Equity | 37.76B | 35.38B | 28.68B | 25.79B | 22.65B | 20.03B |
Cash Flow | ||||||
| Free Cash Flow | 6.05B | 6.25B | 3.64B | 2.90B | 2.47B | 2.12B |
| Operating Cash Flow | 6.49B | 6.74B | 3.86B | 3.12B | 2.74B | 2.58B |
| Investing Cash Flow | -11.64B | -7.15B | -1.39B | 1.07B | -5.94B | -2.26B |
| Financing Cash Flow | 5.62B | 1.55B | -6.07B | -753.70M | -818.14M | 3.42B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Negative. The current price of 32.36 is below the 20-day moving average (MA) of 32.66, below the 50-day MA of 33.56, and below the 200-day MA of 34.06, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 31.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3692.
Hansoh Pharmaceutical Group Company Limited Peers Comparison
Overall Rating
HK:151377Outperform- HK:369274.5Outperform
HK:332068Neutral
HK:086761Neutral
HK:219657Neutral
HK:001345Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1513 | 77Outperform | HKD 26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% |
| HK:3692 | 75Outperform | HKD 196.24B | 24.96 | 18.26% | 1.50% | 24.97% | 43.23% |
| HK:3320 | 68Neutral | HKD 29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% |
| HK:0867 | 61Neutral | HKD 23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% |
| HK:2196 | 57Neutral | HKD 65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0013 | 45Neutral | HKD 18.13B | 143.19 | 1.43% | ― | -8.55% | -96.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3692 | Hansoh Pharmaceutical Group Company Limited | 32.36 | -2.99 | -8.45% | |
| HK:0013 | HUTCHMED (China) Limited | 20.78 | -2.98 | -12.54% | |
| HK:0867 | China Medical System Holdings | 9.81 | -3.65 | -27.10% | |
| HK:1513 | Livzon Pharmaceutical Group Class H | 23.18 | -5.02 | -17.81% | |
| HK:2196 | Shanghai Fosun Pharmaceutical (Group) Co Class H | 16.47 | -6.58 | -28.55% | |
| HK:3320 | China Resources Pharmaceutical Group Ltd. | 4.63 | -0.11 | -2.26% |
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Strikes Multibillion-Dollar ADC Pact With Roche to Expand Global Footprint
Hansoh Pharmaceutical Group has entered a strategic collaboration and license agreement with F. Hoffmann-La Roche Ltd covering a broad portfolio of Antibody-Drug Conjugate programs, including Hansoh’s preclinical assets and new projects based o...
Hansoh’s Aumolertinib EU Application Validated by EMA
Hansoh Pharmaceutical Group has resubmitted its marketing authorization application for the targeted lung cancer therapy Aumolertinib, marketed as Aumseqa outside China, to the European Medicines Agency. The application, covering first-line and mutat...
Hansoh Faces EU Setback on Aumolertinib but Vows Rapid Reapplication
Hansoh Pharmaceutical said the European Commission has revoked the EU marketing authorization for its lung cancer drug Aumolertinib, marketed as Aumseqa outside China, due to a procedural issue linked to the use of AstraZeneca’s TAGRISSO trial...
Hansoh Pharma’s Osteosarcoma Biologic HS-20093 Accepted for Review by China’s NMPA
Hansoh Pharmaceutical Group has announced that China’s National Medical Products Administration has accepted its biologics license application for HS-20093, branded as risvutatug rezetecan for injection. The therapy is intended for osteosarcoma...
Hansoh’s Osteosarcoma Drug HS-20093 Wins NMPA Priority Review in China
Hansoh Pharmaceutical announced that its drug candidate HS-20093, known as risvutatug rezetecan for injection, has been accepted into China’s National Medical Products Administration Priority Review and Approval Procedure. The indication covers...
Hansoh Pharma’s TYK2 Psoriasis Drug Clears Key Phase III Trial Milestone
Hansoh Pharmaceutical said its self-developed TYK2 inhibitor HS-10374 achieved significant efficacy in a pivotal Phase III trial for adults with moderate-to-severe plaque psoriasis, with markedly higher PASI 75 and sPGA 0/1 response rates versus plac...
Hansoh Pharma Wins NMPA Nod for Clinical Trials of Innovative Cancer Drug HS-20197
Hansoh Pharmaceutical Group has received clinical trial approval from China’s National Medical Products Administration for HS-20197 for injection, a self-developed Class 1 innovative medicine. The therapy is intended for investigation in patien...
Hansoh’s Lung Cancer Drug HS-20093 Wins NMPA Priority Review
Hansoh Pharmaceutical Group announced that risvutatug rezetecan for injection (HS-20093), targeted at small cell lung cancer patients whose disease has progressed after prior platinum-based chemotherapy, has been accepted into the National Medical Pr...
Hansoh Pharma’s HS-20093 ADC for Small Cell Lung Cancer Accepted by China’s NMPA
Hansoh Pharmaceutical Group announced that China’s National Medical Products Administration has accepted its biologics license application for HS-20093 for injection. The drug is a proprietary B7-H3 directed antibody-drug conjugate intended for...
Hansoh boosts profit on innovative drugs as lung cancer portfolio wins EU and China approvals
Hansoh Pharmaceutical Group reported strong interim results for the six months ended June 30, 2026, with revenue rising 11.7% to RMB8.304 billion and innovative medicines contributing RMB7.092 billion, or 85.4% of total sales. Profit surged 35.8% to...
Hansoh Pharmaceutical Declares Interim Dividend for First Half of 2026
Hansoh Pharmaceutical Group Company Limited has declared an interim ordinary cash dividend of HKD 0.285 per share for the six months ended June 30, 2026, for the financial year ending December 31, 2026. The ex-dividend date is set for September 22, 2...
Hansoh Pharma Wins NMPA Nod for Clinical Trials of New Cholesterol Drug
Hansoh Pharmaceutical Group said its self-developed Class 1 innovative drug candidate HS-10582, formulated as tablets, has received clinical trial approval from China’s National Medical Products Administration. The company plans to evaluate the...
Hansoh Pharmaceutical Schedules Board Meeting to Approve Interim Results and Dividend
Hansoh Pharmaceutical Group Company Limited plans to convene a board meeting on August 26, 2026, to review and approve its interim financial results for the six months ended June 30, 2026. The board will also consider the declaration of an interim di...
Hansoh’s Osteosarcoma Drug HS-20093 Hits Phase III Target, China Filing Planned
Hansoh Pharmaceutical said its proprietary B7-H3 directed antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase III trial for osteosarcoma patients who had progressed or relapsed after at least two prior systemic therapies...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026